Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maybe SL raised a claw at it, lol.
Regarding Uranium:
EXC - Exelon 1st-qtr earnings jump 73 percent
NEW YORK, April 25 (Reuters) - Exelon Corp. (EXC.N: Quote, Profile , Research), the No. 1 U.S. nuclear power company, posted a 73 percent rise in quarterly profit on Wednesday, boosted by improved margins on its competitive energy sales and higher nuclear power output.
"Strong, better-than-expected," analyst Daniele Seitz said of the results, citing "good demand and very good production" from Exelon power plants." But Seitz, an analyst at Dalhman Rose, who has a buy rating on the company and owns no shares, said Exelon's Illinois utility is still having problems.
Exelon, which canceled a planned takeover of Public Service Enterprise Group Inc. (PEG.N: Quote, Profile , Research) last fall because of regulatory problems, said first-quarter net income rose to $691 million, or $1.02 per share, from $400 million, or 59 cents per share, a year earlier.
Excluding special items, operating earnings were $1.07 per share. Analysts on average had expected the company to earn 99 cents per share in the first quarter, according to Reuters Estimates.
Exelon stock was up 16 cents at $75.15 in morning trading on the New York Stock Exchange.
First-quarter sales jumped 25 percent to $4.8 billion at Exelon, which distributes electricity to 5.4 million customers in Illinois and Pennsylvania and natural gas to more than 480,000 customers in southeastern Pennsylvania.
Exelon stood by its earnings outlook for 2007 of $4.10 to $4.40 per share. Excluding special items, it expects to earn $4.00 to $4.30 per share for the full year.
Analysts are expecting the company to post $4.32 per share excluding special items for 2007, according to Reuters Estimates.
The company said its forecast excludes any additional impact from possible legislation and settlement outcomes on electricity rates in Illinois, beyond the $44 million the company recently proposed to spend on rate relief in 2007.
The Illinois House of Representative last month passed a rate freeze extension bill that would roll back and cap electricity rates to 2006 levels for the state's utilities. Last week, the Senate passed a one-year rate freeze bill that excluded Exelon's Commonwealth Edison utility.
Exelon reiterated its position that a rate freeze extension would cost its ComEd unit $1.4 billion annually and would put it on the path to bankruptcy. The company this week also proposed a $64 million relief package for customers hardest hit by the January rate hikes.
The relief program is expected to cost $44 million in 2007 and about $20 million in 2007 and 2008 combined, said Exelon.
Shares of the integrated power company have risen more than 30 percent in the past year, tracking the broader Standard & Poor's utility index gain of about 33 percent.
Increased power demand has helped push the utility index to near its lifetime high, as the sector continues rebounding from the 2001-2002 industry meltdown that resulted from Enron's bankruptcy and western states' electricity debacle.
EXC - Exelon 1st-qtr earnings jump 73 percent
NEW YORK, April 25 (Reuters) - Exelon Corp. (EXC.N: Quote, Profile , Research), the No. 1 U.S. nuclear power company, posted a 73 percent rise in quarterly profit on Wednesday, boosted by improved margins on its competitive energy sales and higher nuclear power output.
"Strong, better-than-expected," analyst Daniele Seitz said of the results, citing "good demand and very good production" from Exelon power plants." But Seitz, an analyst at Dalhman Rose, who has a buy rating on the company and owns no shares, said Exelon's Illinois utility is still having problems.
Exelon, which canceled a planned takeover of Public Service Enterprise Group Inc. (PEG.N: Quote, Profile , Research) last fall because of regulatory problems, said first-quarter net income rose to $691 million, or $1.02 per share, from $400 million, or 59 cents per share, a year earlier.
Excluding special items, operating earnings were $1.07 per share. Analysts on average had expected the company to earn 99 cents per share in the first quarter, according to Reuters Estimates.
Exelon stock was up 16 cents at $75.15 in morning trading on the New York Stock Exchange.
First-quarter sales jumped 25 percent to $4.8 billion at Exelon, which distributes electricity to 5.4 million customers in Illinois and Pennsylvania and natural gas to more than 480,000 customers in southeastern Pennsylvania.
Exelon stood by its earnings outlook for 2007 of $4.10 to $4.40 per share. Excluding special items, it expects to earn $4.00 to $4.30 per share for the full year.
Analysts are expecting the company to post $4.32 per share excluding special items for 2007, according to Reuters Estimates.
The company said its forecast excludes any additional impact from possible legislation and settlement outcomes on electricity rates in Illinois, beyond the $44 million the company recently proposed to spend on rate relief in 2007.
The Illinois House of Representative last month passed a rate freeze extension bill that would roll back and cap electricity rates to 2006 levels for the state's utilities. Last week, the Senate passed a one-year rate freeze bill that excluded Exelon's Commonwealth Edison utility.
Exelon reiterated its position that a rate freeze extension would cost its ComEd unit $1.4 billion annually and would put it on the path to bankruptcy. The company this week also proposed a $64 million relief package for customers hardest hit by the January rate hikes.
The relief program is expected to cost $44 million in 2007 and about $20 million in 2007 and 2008 combined, said Exelon.
Shares of the integrated power company have risen more than 30 percent in the past year, tracking the broader Standard & Poor's utility index gain of about 33 percent.
Increased power demand has helped push the utility index to near its lifetime high, as the sector continues rebounding from the 2001-2002 industry meltdown that resulted from Enron's bankruptcy and western states' electricity debacle.
TSO approaching $114.
The youtube Suck My Nasdaq guy (former stock broker, but relegated to diaper changing) called this yesterday, remarkable lol. He said AMZN would be down down down in aftermakret, but he is also wrong 90% of the time, lol. Too damn funny. He has the bizarro midas touch, lol.
XOM earnigs tomorrow, I'm going to continue holding $80 May calls overnight that I bought in the 0.7s. Wish me luck, lol
AA (in my 401k, not playing options) nice pop today.
And got to love BHI...OIH is doing great, and so are my refiners. Nice pop on FTO today, and my favorite TSO is flexing too.
And wowzers on AMZN, lol.
Amazon.com (AMZN) $52.5 May calls:
+1,266.67%
Weeeeeee lol.
VION getting jiggy in premarket.
FTO - Frontier Oil ups share buyback funds, raises div
Tue Apr 24, 2007 4:51pm ET
SAN FRANCISCO, April 24 (Reuters) - Oil refiner Frontier Oil Corp. (FTO.N: Quote, Profile , Research) said on Tuesday it raised its share repurchase authorization by $100 million and increased its quarterly dividend to 5 cents a share from 3 cents.
The dividend is payable July 11 to stockholders of record June 29.
Houston-based Frontier Oil said it had repurchased $28.3 million of stock to date under its previous $100 million authorization, leaving $171.7 million approved for future buybacks.
HA - Hawaiian Holdings to Present at the Bear Stearns Global Transportation Conference
Tuesday April 24, 8:00 am ET
HONOLULU, April 24 /PRNewswire-FirstCall/ -- Hawaiian Holdings, Inc. (Amex: HA; PCX) ("Holdings" or "the Company"), parent company of Hawaiian Airlines, Inc. ("Hawaiian"), announced today that Peter Ingram, the Company's CFO, will be presenting at the Bear Stearns Global Transportation Conference to be held May 8-9, 2007 at Bear Stearns World Headquarters, 383 Madison Avenue at 47th Street, in New York City.
Hawaiian Airlines' presentation is scheduled for Wednesday, May 9, 2007 at 10:30 a.m. Eastern Time.
The presentation will be webcast live and will be available on the Investor Relations section of Hawaiian Airlines' website at www.hawaiianair.com. For those who are not available to listen to the live broadcast, the call will be archived.
About Hawaiian Airlines
Hawaiian Airlines, holder of a record 36 consecutive months as America's most punctual airline, has consistently led the nation's carriers in on-time schedule performance and fewest misplaced bags in 2005 and 2006 (as reported by the U.S. Department of Transportation). Consumer surveys by Conde Nast Traveler, Travel + Leisure, and Zagat all rank Hawaiian as the top domestic airline serving Hawaii.
Now in its 78th year of continuous service in Hawaii, Hawaiian is the state's biggest and longest-serving airline, as well as the second largest provider of passenger air service between the U.S. mainland and Hawaii. Hawaiian offers nonstop service to Hawaii from more U.S. gateway cities than any other airline (nine), as well as service to Australia, American Samoa and Tahiti. Hawaiian also provides approximately 100 daily jet flights among the Hawaiian Islands.
Hawaiian Airlines, Inc. is a subsidiary of Hawaiian Holdings, Inc. (Amex: HA; PCX). Additional information is available at HawaiianAirlines.com.
--------------------------------------------------------------------------------
Source: Hawaiian Holdings, Inc.
You can disable script debugging in IE by doing the following in IE:
Tools/Internet Options/Advanced/Disable Script Debugging
Do tell. What questions are you referring to?
Reminds me of this:
Sometimes I think the US is unpresidented.
I was just at the casino down the road and made a 400% gain, quit while I was ahead playing blackjack, and thought of an analogy to the penny market.
The penny market is a casino where you pay to be an employee and receive no salary, but the management lets you occassionally steal from the register when the casino is busy, lol.
If ANX hits 3.5 in the near term, the options will be worth $1.47 at the bid for a 63% gain. That's my target.
You can put your chinden in the oven, but that don't make them biscuits.
http://louminatti.blogspot.com/2006/07/quanell-x-is-great-guy.html
January 2008 $2.5 strike calls, at 90 cents today.
Picture perfect, lol.
ANX upticking into close.
+12% atm.
Just needs a little news or pumping, lol. Preferably news.
That is one large OS.
1.287560507 quintillion.
------------
Posted by: sublime
In reply to: Stock Lobster who wrote msg# 55511 Date:4/24/2007 3:05:43 PM
Post #of 55521
WNMI as of 02-06-07 verified by ff
AS ~ 2 billion
OS ~ 1,287,560,507 billion
Careful. If you mention it, it will move, lol.
VION - Vion Pharmaceuticals Inc. - short interest: 763,168
Short % of Float (as of 12-Mar-07): 1.20%
Not much.
Float: 63.55M
Up on no news, only thing I can find is the insider that has been gobbling up shares bought more and the form 4 was reported today.
ISEE - Emerging Vision Inc
Currently trading around 20 cents.
Shares Outstanding: 70.32M
Float: 34.06M
% Held by Insiders4: 73.70%
Director Ross Harvey owns 3,309,553 shares
http://www.secform4.com/insider-trading/1002554.htm
Chart looks like it trades mighty thin, trending slowly up.
Company Background
Emerging Vision, Inc. (Emerging) operates and franchises retail optical stores (Sterling Stores) in the United States. Emerging and its franchisees operate retail optical stores under the trade names, Sterling Optical, Site For Sore Eyes, Duling Optical and Singer Specs, although most stores (other than Site for Sore Eyes stores located in Northern California) operate under the name, Sterling Optical. As of December 31, 2005, there were 159 Sterling Stores in operation, consisting of 12 Company-owned stores (two of which were being managed by franchisees) and 147 franchised stores. The Company also operates VisionCare of California, Inc. (VCC), a specialized healthcare maintenance organization licensed by the State of California, Department of Managed Health Care, which employs licensed optometrists who render services in offices located immediately adjacent to, or within, most Sterling Stores located in California.
Almost there.
Kal - Callisto Pharmaceuticals, Inc. , AMEX
Trading in the $0.7s
Float: 36.19M
May be something to radar, maybe a gap up tomorrow looking at today's chart.
http://www.secform4.com/insider-trading/1142380.htm
Rodman and Renshaw Releases Research Report on Callisto Pharmaceuticals, Inc.
Tuesday April 24, 10:37 am ET
Initiates Coverage with Market Outperform Rating and a price target of $3.00 per share
NEW YORK, April 24 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments for cancer and inflammatory diseases, announced that Rodman and Renshaw has issued a research report with a "Market Outperform" rating and a price target of $3.00 per share.
About Rodman and Renshaw
Rodman & Renshaw, LLC is a privately-held, full-service investment bank committed to fostering the long-term success of emerging growth companies through capital raising, strategic advice, insightful research, and the development of institutional support. Rodman employs dedicated, experienced, and talented professionals within its equity research, corporate finance, and sales & trading divisions.
About Callisto Pharmaceuticals, Inc.
Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and other serious afflictions. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs in pre-clinical development for other significant health care markets, including ulcerative colitis. One of the Company's lead drug candidates, Atiprimod, is in development to treat advanced carcinoid cancer, a neuroendocrine tumor, and in relapsed or refractory multiple myeloma, a blood cancer. Atiprimod is currently in a Phase II clinical trial in advanced carcinoid cancer patients, and in Phase I/IIa human clinical trials in relapsed or refractory multiple myeloma patients, respectively. A second anti-cancer drug, L-Annamycin, is being developed as a treatment for forms of relapsed or refractory acute leukemia, a currently incurable blood cancer. L-Annamycin, a new compound from the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives. Callisto also has drugs in preclinical development for gastro-intestinal inflammation, and cancer. Guanilib is the lead candidate of our Guanylate Cyclase Receptor Agonist (GCRA) platform. Callisto own worldwide patent coverage for therapeutic applications of Guanilib in cancer and GI inflammatory diseases. Guanilib is expected to enter clinical trial in inflammatory bowel disease in 2008. Callisto has exclusive worldwide licenses from AnorMED Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and L-Annamycin, respectively. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. More information is available at http://www.callistopharma.com.
Answer: What a seal says while making money.
Posted by: power_forward72
In reply to: None Date:4/24/2007 1:17:36 PM
Post #of 55462
AURC AURC AURC
I agree. Small float and good support, and its in the power zone FWIW, lol =)
Insiders bought VION when it was trading at $1.5 - $1.75
http://www.secform4.com/insider-trading/944522.htm
LOL so true!
Quite a few small cap biotechs on the AMEX too.
Safer, more steady gains, more liquid, and DD actually means something.
Grabbed a little WNRW for purely chart aesthetic reasons.
ANX - Adventrx Pharmaceuticals
Trading in mid $2 range, up today.
Float: 60.99M
Trades options (which i like)
Company Background
ADVENTRX Pharmaceuticals, Inc. (ADVENTRX) is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments. The Company's products include CoFactorp (ANX-510), which is a folate-based biomodulator drug; Vinorelbine emulsion (ANX-530), which is a chemotherapeutic agent indicated as a single agent or in combination with cisplatin for treatment of advanced non-small cell lung cancer (NSCLC); Selone, which is a compound in a class of drugs known as organoselenones, and Thiovir, which is a spectrum anti-viral compound that has been shown to inhibit Human Immunodeficiency Virus (HIV), herpes and influenza A viruses.
January 2008 $2.5 calls:
DJIA flirting with 13000 again
VION +6%
Looks ready to move again maybe.